ArticleWorld journal of surgical oncology2026
Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study using inverse probability of treatment weighting.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBowel resection is necessary during cytoreductive surgery for advanced ovarian cancer to achieve optimal cytoreduction, but is associated with increased life-threatening complications and delays in adjuvant chemotherapy, negatively impacting survival. While studies demonstrate deteriorating survival outcomes with increasing bowel resections during primary cytoreductive surgery, data regarding survival impact during interval cytoreductive surgery (ICS) remains limited and conflicting. Therefore, this study aims to evaluate the survival impact of bowel resection performed during ICS in patients with advanced ovarian cancer.
methodsThree hundred thirty patients with advanced ovarian cancer who underwent ICS between 2018 and 2022 were retrospectively reviewed and classified into three groups: no bowel surgery (n = 93), bowel tumor stripping (n = 176), and bowel resection (n = 61). Primary outcome were progression-free survival (PFS) and overall survival (OS). An exploratory analysis was also conducted to examine the effect of bowel resection on post-recurrence progression-free survival 2 (PFS2). Survival analyses were performed using Kaplan-Meier methods and Cox regression models. Propensity score-based inverse probability of treatment weighting (IPTW) was applied to balance between-group differences.
resultsBowel resection during ICS was associated with increased surgical complexity, perioperative morbidity, and postoperative complications. After IPTW adjustment, bowel resection during ICS was an independent risk factor for OS compared to bowel tumor stripping (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.07–3.13, P = 0.027) but had no impact on PFS (HR 1.22, 95% CI 0.78–1.91, P = 0.391). Patients undergoing bowel tumor stripping had comparable survival outcomes to those without bowel involvement (PFS: HR 0.98, 95% CI 0.71–1.34, P = 0.877; OS: HR 0.85, 95% CI 0.54–1.33, P = 0.473). In exploratory analysis of patients with available post-recurrence data, bowel resection during ICS was also an independent risk factor for post-recurrence PFS2 compared to bowel tumor stripping (HR 1.74, 95% CI 1.10–2.76, P = 0.019).
conclusionsBowel resection during ICS impairs long-term survival (OS and PFS2) compared to bowel tumor stripping, while bowel tumor stripping yields survival outcomes comparable to no bowel involvement. These findings highlight the importance of individualized surgical planning regarding bowel procedures during ICS, with careful consideration of the risk-benefit balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.